113 related articles for article (PubMed ID: 12719749)
21. Prognostic factors for renal cell carcinoma with tumor thrombus extension.
Klatte T; Pantuck AJ; Riggs SB; Kleid MD; Shuch B; Zomorodian N; Kabbinavar FF; Belldegrun AS
J Urol; 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. PubMed ID: 17698087
[TBL] [Abstract][Full Text] [Related]
22. [Recent management of renal cell carcinoma].
Nishio Y; Yoshida O
Gan To Kagaku Ryoho; 1988 Feb; 15(2):219-23. PubMed ID: 3257677
[TBL] [Abstract][Full Text] [Related]
23. [Role of surgery (cytoreductive nephrectomy and metastasectomy) in the management of metastatic renal cell carcinoma: a literature review].
Arroua F; Maurin C; Carcenac A; Ragni E; Rossi D; Bastide C
Prog Urol; 2010 Dec; 20(13):1175-83. PubMed ID: 21130395
[TBL] [Abstract][Full Text] [Related]
24. Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma.
Lee CP; Patel PM; Selby PJ; Hancock BW; Mak I; Pyle L; James MG; Beirne DA; Steeds S; A'Hern R; Gore ME; Eisen T
J Clin Oncol; 2006 Feb; 24(6):898-903. PubMed ID: 16484699
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant and adjuvant treatment of renal cell carcinoma.
Thillai K; Allan S; Powles T; Rudman S; Chowdhury S
Expert Rev Anticancer Ther; 2012 Jun; 12(6):765-76. PubMed ID: 22716493
[TBL] [Abstract][Full Text] [Related]
26. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
Daliani DD; Papandreou CN; Thall PF; Wang X; Perez C; Oliva R; Pagliaro L; Amato R
Cancer; 2002 Aug; 95(4):758-65. PubMed ID: 12209719
[TBL] [Abstract][Full Text] [Related]
27. A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma.
Srinivas S; Guardino AE
BJU Int; 2005 Sep; 96(4):536-9. PubMed ID: 16104906
[TBL] [Abstract][Full Text] [Related]
28. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy.
Karam JA; Wood CG
Hematol Oncol Clin North Am; 2011 Aug; 25(4):753-64. PubMed ID: 21763966
[TBL] [Abstract][Full Text] [Related]
29. Surgery for renal cell carcinoma metastases.
Breau RH; Blute ML
Curr Opin Urol; 2010 Sep; 20(5):375-81. PubMed ID: 20592612
[TBL] [Abstract][Full Text] [Related]
30. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R
Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
[TBL] [Abstract][Full Text] [Related]
31. Current clinical trials in renal cell carcinoma.
Sokoloff MH; Daneshmand S; Ryan CW
Urol Oncol; 2005; 23(4):289-92. PubMed ID: 16018946
[TBL] [Abstract][Full Text] [Related]
32. [Localized and locally advanced renal cell carcinoma: method of outcome prognosis].
Serniak IuP
Urol Nefrol (Mosk); 1998; (1):32-5. PubMed ID: 9532944
[TBL] [Abstract][Full Text] [Related]
33. Oncological outcomes in patients undergoing radical nephrectomy and vena cava thrombectomy for renal cell carcinoma with venous extension: a single-centre experience.
Parra J; Drouin SJ; Hupertan V; Comperat E; Bitker MO; Rouprêt M
Eur J Surg Oncol; 2011 May; 37(5):422-8. PubMed ID: 21330093
[TBL] [Abstract][Full Text] [Related]
34. [Survival analysis of interferon-alpha on locally advanced clear cell renal cell carcinoma after radical nephrectomy].
Xia J; Li X; Chen XQ; Li X; Zeng H; Wei Q; Zhang P; Zhu YC
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Jan; 43(1):91-4. PubMed ID: 22455140
[TBL] [Abstract][Full Text] [Related]
35. [Carcinoma of the collecting ducts of Bellini: a case report with cutaneous metastasis as the initial clinical manifestation].
Grande M; Facchini F; La Rosa M; Pozzoli GL; Leone M; Piana S; Monica B
Urologia; 2010; 77 Suppl 16():51-4. PubMed ID: 21104663
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease.
Wood CG; Margulis V
Cancer; 2009 May; 115(10 Suppl):2355-60. PubMed ID: 19402066
[TBL] [Abstract][Full Text] [Related]
37. [Bilateral synchronous renal cell carcinoma: report of three cases].
Nakatsuji H; Yamashita Y; Karashima T; Hashine K; Sumiyoshi Y
Hinyokika Kiyo; 1999 Oct; 45(10):695-8. PubMed ID: 10586361
[TBL] [Abstract][Full Text] [Related]
38. Renal cell carcinoma: current status and future prospects.
Drucker BJ
Cancer Treat Rev; 2005 Nov; 31(7):536-45. PubMed ID: 16236454
[TBL] [Abstract][Full Text] [Related]
39. Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy.
Kedar I; Mermershtain W; Ivgi H
Int J Cancer; 2004 Jun; 110(2):260-5. PubMed ID: 15069691
[TBL] [Abstract][Full Text] [Related]
40. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
Amato RJ; Morgan M; Rawat A
Cancer; 2006 Apr; 106(7):1498-506. PubMed ID: 16475152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
